Azidothymidine (AZT) in the treatment of symptomatic HIV-1-infected hemophiliacs.
Twenty-one immunodeficiency virus 1 (HIV 1)-positive hemophilic patients were treated with Azidothymidine (AZT) for symptomatic HIV infection. The median observation period was 20.5 months. At 25 months the probability of survival was 82%, the probability of progression of disease from CDC III or IV C2 to IV C1 (AIDS) was 20% in patients on continuous AZT treatment and 50% in patients with interruption of treatment. Three patients developed severe leukopenia and 3 patients severe anemia during AZT treatment. In 1 patient a dose-dependent striking increase of transaminases during AZT treatment was observed. In 7 patients treatment was interrupted, in 1 patient because of anemia, in 1 because of pruritus and in 5 patients because of non-compliance. No significant changes in the consumption of clotting factor concentrates and number of bleeding episodes before and during AZT treatment were noted. We conclude, that both hematological and non-hematological side effects of AZT in HIV 1-infected hemophilic patients are comparable to those seen in other risk groups. AZT does not increase the bleeding tendency in this patient group.
Eichinger
S
S
First Department of Medicine, University of Vienna, Austria.
Pabinger
I
I
Hartl
H
H
Stain
C
C
Mayerhofer
S
S
Schweiger
C
C
Kier
P
P
Schwarzinger
I
I
Kyrle
P A
PA
Lechner
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D001772:Blood Cell Count / Q000187:drug effects; D001779:Blood Coagulation Factors / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D004797:Enzyme-Linked Immunosorbent Assay; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D015497:HIV-1; D006467:Hemophilia A / Q000150:complications*; D006801:Humans; D016130:Immunophenotyping; D008099:Liver / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D015996:Survival Rate; D065227:Transfusion Reaction; D015215:Zidovudine / Q000009:adverse effects* / Q000627:therapeutic use*
D001779:Blood Coagulation Factors; D015215:Zidovudine